Objective-The role of plasminogen activator inhibitor-1 (PAI-1) in vein graft (VG) remodeling is undefined. We examined the effect of PAI-1 on VG intimal hyperplasia and tested the hypothesis that PAI-1 regulates VG thrombin activity.
I
nternal thoracic arteries and saphenous veins are used to perform coronary artery bypass grafting in patients with advanced coronary artery disease. However, the development of obstructive disease is significantly more common in venous than arterial grafts, with approximately 40% of vein grafts (VGs) occluding within 10 years after coronary artery bypass grafting. 1 The initial pathophysiological process in adverse VG remodeling is intimal hyperplasia. Although some degree of intimal hyperplasia in VGs is an adaptive response to arterial blood pressure and flow, excessive intimal hyperplasia is common and constitutes the substrate for the development of VG atherosclerosis. The molecular and cellular processes that regulate intimal hyperplasia within VGs are poorly understood and likely exhibit significant differences from those that regulate intimal hyperplasia in native arteries. Hence, additional studies are needed to define the factors that regulate intimal hyperplasia in VGs.
Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of tissue-type plasminogen activator and urinary-type plasminogen activator. 2 PAI-1 is present in plasma, platelets, endothelial cells, vascular smooth muscle cells (SMC), and extracellular matrix (ECM). PAI-1 binds to and is stabilized by its cofactor, vitronectin (VN), which is present in plasma and ECM. 3 In addition to regulating fibrinolysis, PAI-1 stimulates migration of vascular SMC by binding to low-density lipoprotein receptor-related protein, present on SMC. 4 However, PAI-1 can also inhibit SMC migration by binding to VN in the ECM, thereby blocking VN binding to integrin and nonintegrin receptors present on SMC. 5 In addition, PAI-1 inhibits thrombin. 6 Given that thrombin stimulates SMC proliferation and is hypothesized to stimulate intimal hyperplasia independently of its prothrombotic effects, [7] [8] [9] it is possible that PAI-1 could regulate intimal hyperplasia by inhibiting thrombin. However, little is known about the roles of PAI-1 in regulating VG intimal hyperplasia and thrombin activity in vivo. Elevated plasma PAI-1 concentration is associated with VG occlusion in humans, 10 and PAI-1 expression is upregulated in obstructed human VGs. 11 However, it is unknown whether PAI-1 actively regulates VG intimal hyperplasia or is simply a biomarker associated with VG disease. Given the potential for PAI-1 to produce both stimulatory and inhibitory effects on cell migration in vitro, it is important to determine the net effects of enhanced and reduced PAI-1 expression on VG intimal hyperplasia in vivo. Consequently, the main objective of this study was to determine the impact of primary alterations in PAI-1 expression, both localized and systemic, on the development of VG intimal hyperplasia. A secondary objective was to examine the potential role of PAI-1 as a thrombin inhibitor in vivo in the VG wall. To accomplish these objectives, we studied wild-type (WT), PAI-1-deficient (Pai1 Ϫ/Ϫ ), and PAI-1-overexpressing mice in a model of vein bypass grafting.
Materials and Methods
A detailed Methods section describing mouse strains, morphometric and immunohistochemical assessments of VGs, measurement of plasma PAI-1, reverse transcription-polymerase chain reaction analysis of PAI-1 gene expression, isolation and functional assessment of venous SMC, and statistical methods is provided in the Supplemental Data, available online at http://atvb.ahajournals.org.
Vein Grafting Surgery
Surgery was performed as described. 12 In brief, the right common carotid artery of a male mouse was ligated proximally and distally and transected at its midportion. The transected ends were each passed through polyethylene cuffs, everted back over them, and secured with ligatures. A segment (1 cm) of inferior vena cava (IVC) was excised from a different (donor) male mouse. The cuffed ends of the transected artery were inserted into each end of the VG and secured with sutures. Blood flow was restored by removing the ligatures, after which the surgical wound was sutured closed. All surgical procedures and histological analyses were performed with the investigator blinded to mouse genotype.
Measurement of Thrombin Activity in VGs
Five days after VG insertion mice were anesthetized. After exposing the heart and lacerating the liver, ice-cold 0.9% NaCl (10 mL) was injected into the left ventricle to flush blood from the vasculature. The VG was exposed, excised, and incised longitudinally. Two VGs retrieved from mice with identical donor/graft genotypes were placed in 0.9% NaCl at 4°C and pulverized with a Pellet Pestle (Kimble Kontes). The homogenate was centrifuged at 9000g for 15 minutes. The supernatant (extract) was collected, and its total protein concentration was determined by the bicinchoninic acid method (BCA Protein Assay, Pierce). Each extract derived from 2 VGs was counted as a single sample for statistical analyses. To measure thrombin activity, aliquots of each extract (20 g) were diluted in assay buffer (50 mmol/L Tris ⅐ HCl, pH 8.3, containing 0.2% BSA, 0.13 mmol/L NaCl, 75 KIU/L aprotinin) that lacked or contained hirudin (1.3 mg/mL). After 1 minute, chromogenic thrombin substrate H-D-Phe-Pip-Arg-paranitroanilide (200 mol/L, S-2238, Chromogenix) was added, and reactions were incubated at 37°C for 2 hours. Absorbance of reaction mixtures at 405 nm (A 405 ) was measured in a microplate spectrophotometer. The difference in A 405 of identical samples analyzed in the presence and absence of hirudin was defined as the thrombin activity of the sample.
Results

PAI-1 and VN Deficiency Exert Distinct Effects on VG Remodeling
To examine the role of PAI-1 in VG remodeling, we compared VG intimal hyperplasia in WT and PAI-1-deficient mice. For these experiments, the genotype of the recipient mouse was the same as that of the VG donor. At 4 weeks after VG implantation, mean intimal thickness and intimal area indexed to lumen area were significantly greater in Pai1 Ϫ/Ϫ mice than in WT mice (Figure 1 ), suggesting that PAI-1 deficiency promotes VG intimal hyperplasia. Enhanced VG neointima formation in PAI-1-deficient mice could result not only from loss of direct effects of PAI-1 on VG remodeling but also from changes in VN function induced by PAI-1 deficiency, given that PAI-1 and VN regulate each other's functions. To address this issue, we studied VG neointima formation in Vn Ϫ/Ϫ mice and mice with combined PAI-1 and VN deficiency (double knockout mice), with the genotypes of all VGs being identical to those of recipient mice. Double knockout mice exhibited significantly greater intimal hyperplasia than Vn Ϫ/Ϫ mice ( Figure 1 ). These results, in conjunction with the data derived from WT and Pai1 Ϫ/Ϫ mice, suggested that PAI-1 deficiency promotes intimal hyperplasia whether or not VN was present-ie, that the effect of PAI-1 deficiency on intimal hyperplasia is not solely mediated indirectly via VN. They also suggested that net effects of deficiency of PAI-1 or VN on VG intimal hyperplasia differ significantly and supported the hypothesis that PAI-1 deficiency promotes the capacity of VN to support intimal hyperplasia, as the proliferative effect of PAI-1 deficiency was significantly less in mice also lacking VN. 
Local and Systemic Expression of PAI-1 Regulate Its Concentration in VGs
PAI-1 is present in the VG wall, 11 although the origin of this pool is poorly defined. To examine this issue, we conducted experiments involving various combinations of VG donors and recipients. VG PAI-1 content was assessed by quantitative immunohistochemistry 4 weeks after surgery. Undetectable or extremely low levels of immunostaining, consistent with background signal, were detected in VGs of Pai1 Ϫ/Ϫgraft / Pai1 Ϫ/Ϫrecipient mice (nϭ7, Figure 2A ), and plasma PAI-1 antigen and activity were undetectable in this group (Table) .
PAI-1 immunostaining was significantly less in VGs of
Pai1
Ϫ/Ϫgraft /WT recipient mice (nϭ6) than in those of WT graft / WT recipient mice ( Figure 2B ), whereas plasma PAI-1 antigen and activity levels did not differ significantly between these groups. PAI-1 immunostaining was significantly higher in VGs of PAI-1-transgenic (Tg) graft /WT recipient mice (nϭ6) than in VGs of WT graft /WT recipient controls (nϭ9), whereas plasma PAI-1 concentration did not differ significantly between these groups. Together, these results suggested that localized vascular expression is an important source of PAI-1 within VG neointima, as PAI-1-Tg and PAI-1-deficient VGs implanted in WT mice had significantly higher and lower concentrations of intimal PAI-1, respectively, compared with WT VGs, despite identical recipient genotypes and a lack of significant difference in plasma PAI-1 concentration between groups.
PAI-1 concentration in VGs of WT graft /Pai1 Ϫ/Ϫrecipient mice were similar to those of WT graft /WT recipient mice ( Figure 2B ), further supporting the important role of local synthesis in determining VG PAI-1 concentration. Control experiments revealed significantly higher PAI-1 concentration in PAI-1-Tg IVC than WT IVC, and real-time reverse transcriptionpolymerase chain reaction analysis revealed an approximately 4-fold increase of PAI-1 gene expression in PAI-1-Tg IVC compared with WT IVC (Supplemental Figure II) . These results confirmed that PAI-1 expression was increased in PAI-1-Tg veins at the time of initial graft implantation. To assess the impact of increased systemic PAI-1 expression on VG PAI-1 concentration, we compared WT graft /PAI-1-Tg recipient mice (nϭ7) with WT graft /WT recipient controls. The former group exhibited significantly higher VG PAI-1 concentration than the latter ( Figure 2B ). Plasma PAI-1 antigen and activity concentrations were significantly higher in WT graft /PAI-1-Tg recipient mice than in WT graft /WT recipient mice (Table) (Figure 3) , suggesting that PAI-1 overexpression does not promote VG intimal hyperplasia. Consistent with these data, intimal hyperplasia in mice with combined overexpression of PAI-1 both locally and systemically (ie, PAI-1-Tg graft /PAI-1-Tg recipient mice) did not differ significantly from that of WT graft /WT recipient mice (Figure 3) . We did not analyze intimal hyperplasia of WT or PAI-1-Tg VGs transplanted into PAI-1-deficient mice because of the anticipated immune reaction to VG PAI-1 in PAI-1-deficient mice.
PAI-1 Regulates Cellular Composition of VG Neointima
We analyzed the composition of VG neointima. Quantitative smooth muscle ␣-actin immunostaining revealed a significant increase in the percentage of smooth muscle ␣-actin-positive area in Pai1 Ϫ/Ϫgraft /Pai1 Ϫ/Ϫrecipient VGs compared with WT graft /WT recipient VGs and all other experimental groups (Supplemental Figure III) , suggesting that PAI-1 deficiency increased not only neointima area but also the density of SMC in neointima, which is consistent with a report that PAI-1 increases ECM accumulation within developing neointima. 13 Differences between other groups and WT graft / WT recipient mice did not achieve statistical significance. There was no significant difference in neointima macrophage concentration between experimental groups (data not shown).
PAI-1 Regulates Venous SMC Proliferation and Migration
SMC express PAI-1 and play a central role in intimal hyperplasia. 14 To identify potential mechanisms underlying our in vivo findings, we isolated WT, PAI-1-deficient, and PAI-1-Tg SMC from mouse vena cava, established cultured lines, and compared their proliferation and migration in vitro. To study proliferation, we cultured SMC with thrombin (1 U/mL) and measured cell proliferation by the 5-bromo-2Ј-deoxyuridine incorporation method. Thrombin-induced proliferation of PAI-1-deficient SMC was significantly greater than that of WT SMC, whereas no significant differences were observed between these groups in the presence of hirudin, a specific thrombin inhibitor ( Figure 4A ). These results suggested that basal rates of venous SMC proliferation are not affected by PAI-1 deficiency but that deficient expression of PAI-1 by venous SMC enhances thrombininduced proliferation. However, we found no significant difference between WT and PAI-1-Tg venous SMC in thrombin-induced proliferation ( Figure 4A ), including in Figure IV) . To study the effect of SMC PAI-1 expression on migration, we added SMC to the surface of 3-dimensional collagen gels and triggered migration of cells through gels with platelet-derived growth factor-BB. PAI-1-Tg and PAI-1-deficient venous SMC both migrated significantly faster than WT SMC ( Figure 4B ), results consistent with a previous study of ours involving arterial SMC. 15
PAI-1 Regulates Fibrin/Fibrinogen Deposition in VG
PAI-1 regulates fibrinolysis, and deposition of fibrin within the vascular wall has been hypothesized to regulate intimal hyperplasia. 16 We used quantitative immunohistochemistry to assess fibrin/fibrinogen concentration in VGs. There was no significant difference in fibrin/fibrinogen concentration in the VG wall of PAI- 
PAI-1 Regulates Thrombin Activity in the VG Wall
It is hypothesized that thrombin signaling promotes intimal hyperplasia. 8, 9 To test the hypothesis that PAI-1 functions in vivo to inhibit thrombin in VGs, we grafted WT vein segments into WT mice and PAI-1-deficient vein segments into PAI-1-deficient mice. After 5 days, VGs were harvested and homogenized, and soluble extracts were prepared. Microscopic examination of longitudinally incised VGs before homogenization revealed no evidence of thrombus. Thrombin activity was significantly greater in VG extracts of Pai1 
Discussion
Several studies have examined fundamental processes by which PAI-1 regulates intimal hyperplasia, including via effects on cell proliferation, migration, and apoptosis. 17 These studies have included analyses of the molecular signaling events underlying the effects of PAI-1 on vascular cell function, including cellular receptors, intracellular signaling pathways, and regulation of ECM proteolysis. Together, they have shown that PAI-1 regulates multiple pathways and exerts effects predicted to both increase and decrease intimal hyperplasia. However, no previous single study has examined the in vivo effects of both primary increases and decreases in vascular wall PAI-1 gene expression on intimal hyperplasia, which is essential to understanding the net effect of abnormal PAI-1 expression on vascular remodeling. Although previous studies examined the role of PAI-1 in regulating intimal hyperplasia in arteries, 9,13,18 -23 we focused this study on the role of PAI-1 in VG remodeling, as PAI-1 accumulates in diseased VG, 11 but it has previously been unknown whether PAI-1 actively regulates VG remodeling or is simply a passive marker of VG disease. The main findings of our study are that (1) PAI-1 regulates VG remodeling, with decreased PAI-1 expression leading to increased intimal hyperplasia; (2) PAI-1's effects are mediated not only by the plasma pool but also by a local VG pool that is not discernable by measurement of plasma PAI-1; (3) a primary increase in PAI-1 expression locally in VG or systemically does not increase VG intimal hyperplasia; (4) PAI-1 regulates the function of VG SMC; and (5) PAI-1 regulates thrombin activity in VGs.
Our data suggest that PAI-1 functions in vivo to regulate the cell adhesion function of VN in VGs. VN is synthesized by vascular SMC and other cell types and secreted into the ECM of the vascular wall, where it binds collagen and supports cell migration. 24 -26 PAI-1 competitively blocks binding of integrins (eg, ␣ V ␤ 3 ) and urinary-type plasminogen activator receptor to VN. 5 Therefore, decreased PAI-1 ex- pression could promote VNЈs interactions with its receptors and increase cell migration. 15 In this study, we showed that PAI-1-deficient venous SMC migrate more rapidly through 3-dimensional collagen matrices than WT venous SMC do. We also showed that the proliferative effect of PAI-1 deficiency is blunted in mice also lacking VN, suggesting that this mechanism (ie, PAI-1 deficiency promoting VNЈs cell adhesive function) is active in vivo in VGs. In a recent study, we showed that VN-deficient arterial SMC migrate faster through 3-dimensional collagen matrix than WT-SMC, and we provided data to suggest that the effect was mediated by an increase in the pool of free, motogenic PAI-1. 15 On the basis of this finding, one might hypothesize that VN deficiency would enhance intimal hyperplasia, which was observed in a carotid artery ligation model. 9 However, we observed reduced VG intimal hyperplasia in VN-deficient mice, suggesting that during early venous remodeling after bypass grafting, VN supports intimal hyperplasia, most likely by increasing integrin-dependent cell migration.
Overexpression of PAI-1 by vascular SMC, as occurs in diabetes mellitus and other diseases, 27 promotes cell proliferation and migration and inhibits apoptosis in vitro. 4, 14, 17 We found that overexpression of PAI-1 by venous SMC promoted their migration through 3-dimensional collagen but did not increase SMC proliferation. However, we did not find that a primary increase of PAI-1 expression, either in VG or systemically, increased VG intimal hyperplasia. These results suggest that although PAI-1 can promote cell migration and proliferation in vitro, the net effect of PAI-1 overexpression on intimal hyperplasia in vivo during the early phase after vein grafting is neutral, perhaps because the proliferative and promigratory effects of PAI-1 are counterbalanced by its antimigratory and antithrombin effects. It is important to realize that our results, observed at a single time point in a murine system, do not disprove the idea that PAI-1 could promote VG intimal hyperplasia at other time points, in other preclinical models, or in human VGs.
An important aspect of our study was the in vivo analysis of the role of PAI-1 as a thrombin inhibitor. Although PAI-1 is known to bind and inhibit thrombin in purified, in vitro systems, 6 little is known about the significance of this molecular interaction in vivo. Active thrombin can be recovered from the VG wall. 28 We have shown that VG thrombin activity is significantly greater in PAI-1-deficient mice, arguing that PAI-1 functions in vivo to regulate vascular wall thrombin activity in VGs. We also showed that PAI-1 produced locally within VGs regulates thrombin and that PAI-1 produced by SMC regulates their proliferative response to thrombin stimulation. Based on our data, we hypothesize that PAI-1 deficiency promotes VG intimal hyperplasia by effects on thrombin. This hypothesis is supported by reports that thrombin stimulates SMC proliferation 7 and by studies suggesting that sustained thrombin signaling after vascular injury promotes intimal hyperplasia independently of effects on thrombosis. 8, 9 Although we found that PAI-1-deficient SMC exhibited hyperresponsiveness to thrombin in vitro, we did not observe lessened thrombin responsiveness in PAI-1-Tg SMC, as might be expected. Although our data do not explain the mechanism underlying this observation, we hypothesize that the antithrombin effects of PAI-1 are counterbalanced by the proliferative effects of PAI-1 overexpression. 14 In future studies, it will be of interest to examine thrombin activity in VN-deficient VGs to examine the in vivo function of VN as a cofactor for inhibition of vascular wall thrombin by PAI-1. 6 In addition to possible effects on thrombin, it is possible that upregulation of plasmin activity could account for the increased intimal hyperplasia observed in PAI-1-deficient mice, as plasmin has been hypothesized to promote cell migration by degrading ECM. 17 However, plasminogen deficiency does not significantly affect VG neointima formation in mice, 29 arguing against plasmin as the downstream mediator of PAI-1 deficiency on VG intimal hyperplasia.
PAI-1 regulates vascular fibrin accumulation, which has been proposed as a potential mechanism by which PAI-1 regulates intimal hyperplasia. 30 We found increased VG fibrin deposition in PAI-1-Tg graft /PAI-1-Tg recipient mice and a nonsignificant trend toward reduced fibrin deposition in PAI-1-deficient VGs. These results suggested that PAI-1 regulates fibrin deposition in the VG wall. However, we did not observe a correlation between VG fibrin accumulation and intimal hyperplasia in PAI-1-overexpressing mice, suggesting that PAI-1-driven fibrin deposition does not in itself promote intimal hyperplasia. We hypothesize that the lack of a proliferative effect of enhanced fibrin deposition may have been due to the potential antimigratory effects of enhanced PAI-1 expression.
Our study has some limitations. Although we used a published method to study intimal hyperplasia in VG, 12 we observed less intimal hyperplasia at 4 weeks after VG implantation than reported previously. The variation between our study and that of Zou et al 12 may be due to minor differences in surgical technique, differences in the location of cross-sections used to assess intimal hyperplasia, and environmental and dietary differences between studies. Our studies involving implantation of genotype-mismatched VGs into recipient mice provided insights into the function of PAI-1 produced locally within VGs during early venous remodeling. However, some of the PAI-1 in VGs observed in our study could be of systemic origin (ie, from plasma or cells that invade VGs from blood or adjacent artery 31, 32 ), which complicates our functional assessment of VG PAI-1. Nevertheless, our analyses of VG and plasma PAI-1 suggest that cells present in VGs at the time of graft insertion (or subsequently derived from them) are the major source of PAI-1 within VG neointima. These results are consistent with published studies that found that the majority of cells present in VGs are derived from the transplanted graft. 33 In summary, we have shown that PAI-1 regulates intimal hyperplasia in a clinically relevant model. Our experiments involving PAI-1-deficient mice and SMC suggest mechanisms by which downregulation of PAI-1 could promote intimal hyperplasia (ie, by enhancing VN-dependent SMC migration and thrombin-induced SMC proliferation). These findings are relevant to ongoing development of PAI-1 inhibitors to treat vascular disease-ie, pharmacological PAI-1 inhibition could potentially upregulate cell migration and VG wall thrombin activity. Our experiments involving PAI-1-Tg mice suggest that PAI-1 overexpression does not necessarily promote intimal hyperplasia. This finding is significant, given that previous clinical studies, based on associations of PAI-1 concentration and VG disease, had hypothesized that increased PAI-1 expression promotes intimal hyperplasia. 10, 11 Additional studies involving large animal models of bypass grafting and chemical inhibitors of PAI-1 are warranted to determine the effects of pharmacological targeting of PAI-1 on venous remodeling under clinically relevant conditions.
